Krystal Biotech Inc (KRYS)
Days of sales outstanding (DSO)
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | 2.20 | 1.35 | 1.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| DSO | days | 165.91 | 271.24 | 363.09 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
March 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ 2.20
= 165.91
The days of sales outstanding (DSO) for Krystal Biotech Inc have shown fluctuations over the past few quarters. As of March 31, 2024, the DSO stood at 165.91 days, representing the average number of days it takes the company to collect revenue from its sales.
Comparing this figure to previous quarters, we observe a significant decrease from the DSO of 271.24 days on December 31, 2023, and a further improvement from the DSO of 363.09 days on September 30, 2023. However, there is missing data for the quarters before September 30, 2023.
A lower DSO indicates that the company is collecting receivables more efficiently, which could be due to improved collection processes, tighter credit policies, or prompt payment from customers. It is essential for Krystal Biotech Inc to monitor and manage its DSO to ensure effective cash flow management and maintain healthy liquidity levels.
Peer comparison
Mar 31, 2024